ArticleClinical ophthalmology (Auckland, N.Z.)2025
Visual Outcomes and Quality of Vision After Bilateral Implantation of a Hydrophobic Acrylic Trifocal Intraocular Lens.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Visual Outcomes and Patient-Reported Dysphotopsia After PanOptix and PanOptix Toric Implantation Stratified by Preoperative Chord Mu: A Prospective Observational Cohort Study.Ophthalmology and therapy · 2026Article
- An Update on Intraocular Lens Technology for Presbyopia Correction and Visual Outcomes.Medical sciences (Basel, Switzerland) · 2026Review
- One-year prospective study of a HEMA-based hydrophobic acrylic trifocal IOL (Clareon PanOptix): visual performance, patient-reported outcomes, and optic clarity.Scientific reports · 2026Article
- Comparison of Visual Performance and Patient Satisfaction Between Two Trifocal Intraocular Lenses: A Prospective, Paired-Eye Comparative Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate visual outcomes and quality of vision following bilateral implantation of a hydrophobic acrylic intraocular lens (IOL) in eyes targeted for emmetropia. Methods: This was a prospective, single arm study. Subjects were bilaterally implanted with the Clareon PanOptix IOL and evaluated at 1 and 3 months postoperatively. Endpoints included binocular uncorrected and distance-corrected visual acuities at distance (UDVA, CDVA), intermediate (UIVA, DCIVA; 60 cm), and near (UNVA, DCNVA; 40 cm, 33 cm), defocus curve, manifest refraction, and administration of a visual disturbance questionnaire (QUVID) and a satisfaction questionnaire (IOLSAT). Results: A total of 24 subjects (48 eyes) completed the study. Mean postoperative binocular CDVA, DCIVA (60 cm), DCNVA (40 cm), and DCNVA (33 cm) were -0.04 ± 0.08 logMAR, -0.08 ± 0.10 logMAR, 0.01 ± 0.10 logMAR, and 0.04 ± 0.11 logMAR, respectively. Mean postoperative binocular UDVA, UIVA (60 cm), UNVA (40 cm), and UNVA (33 cm) were 0.02 ± 0.19 logMAR, -0.08 ± 0.09 logMAR, 0.04 ± 0.12 logMAR, and 0.08 ± 0.15 logMAR, respectively. Overall, postoperative spectacle independence at distance, intermediate, and near were 100%, 93%, and 73%, respectively. A total of 9%, 12%, and 0% of subjects were bothered "quite a bit" or "very much" by halos, starburst, and glare, respectively. Conclusion: The results of this study suggest that bilateral implantation with the Clareon PanOptix can achieve excellent visual outcomes, high spectacle independence, and low reports of bothersome dysphotopsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.